Literature DB >> 31135703

Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).

Ming-Shun Hsieh1,2,3,4, Chorng-Kuang How3,4, Vivian Chia-Rong Hsieh5, Pau-Chung Chen1,6.   

Abstract

BACKGROUND: Several studies have reported improved sepsis outcomes when certain preadmission antihypertensive drugs, namely, calcium channel blockers (CCBs), are used. This study aims to determine whether preadmission antihypertensive drug use, especially angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), is associated with decreased total hospital mortality in sepsis.
METHODS: This study was conducted using the unique database of a sepsis cohort from the National Health Insurance Research Database in Taiwan. Frequency matching for age and sex between preadmission antihypertensive drug users (study cohort) and nonusers (comparison cohort) was conducted. The primary outcome was total hospital mortality. Logistic regression analyses were performed to calculate the odds ratios (ORs) of important variables. Further joint effect analyses were carried out to examine the impacts of different combinations of antihypertensive drugs.
RESULTS: A total of 33,213 sepsis antihypertensive drug use patients were retrieved as the study cohort, and an equal number of matched sepsis patients who did not use antihypertensive drugs were identified as the comparison cohort. The study cohort had a higher incidence rate of being diagnosed with septic shock compared with the comparison cohort (4.36%-2.31%, P < 0.001) and a higher rate of total hospital mortality (38.42%-24.57%, P < 0.001). In the septic shock condition, preadmission antihypertensive drug use was associated with a decreased adjusted OR (OR = 0.66, 95% confidence interval [CI], 0.55-0.80) for total hospital mortality, which was not observed for the nonseptic shock condition. Compared with antihypertensive drug nonusers, both ACEI and ARB users had decreased adjusted ORs for total hospital mortality in sepsis (adjusted OR = 0.93, 95% CI, 0.88-0.98 and adjusted OR = 0.85, 95% CI, 0.81-0.90); however, CCB, beta-blocker, and diuretic users did not. In the septic shock condition, ACEI, ARB, CCB, and beta-blocker users all had decreased ORs for total hospital mortality. Joint effect analysis showed ACEI use, except in combination with diuretics, to be associated with a decreased adjusted OR for total hospital mortality in sepsis. Similar results were observed for ARB users.
CONCLUSIONS: Preadmission ACEI or ARB use is associated with a decreased risk of total hospital mortality, regardless of a nonshock or septic shock condition.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31135703     DOI: 10.1097/SHK.0000000000001382

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  12 in total

1.  Occurrence and Impact of Gastrointestinal Bleeding and Major Adverse Cardiovascular Events during Sepsis: A 15-Year Observational Study.

Authors:  Ming-Shun Hsieh; Shu-Hui Liao; Vivian Chia-Rong Hsieh; Chorng-Kuang How
Journal:  Emerg Med Int       Date:  2020-09-27       Impact factor: 1.112

2.  Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.

Authors:  Ming-Shun Hsieh; Sung-Yuan Hu; Shu-Hui Liao; Chia-Ming Chang; Vivian Chia-Rong Hsieh; Chorng-Kuang How
Journal:  Emerg Med Int       Date:  2021-07-23       Impact factor: 1.112

3.  The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review.

Authors:  Kaiquan Tan; Martin Harazim; Benjamin Tang; Anthony Mclean; Marek Nalos
Journal:  Crit Care       Date:  2019-09-04       Impact factor: 9.097

Review 4.  Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.

Authors:  Nicholas E Ingraham; Abdo G Barakat; Ronald Reilkoff; Tamara Bezdicek; Timothy Schacker; Jeffrey G Chipman; Christopher J Tignanelli; Michael A Puskarich
Journal:  Eur Respir J       Date:  2020-07-09       Impact factor: 16.671

5.  Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection.

Authors:  James A Russell; John C Marshall; Arthur Slutsky; Srinivas Murthy; Dave Sweet; Terry Lee; Joel Singer; David M Patrick; Bin Du; Zhiyong Peng; Matthew Cheng; Kevin D Burns; Michael O Harhay
Journal:  BMJ Open       Date:  2020-12-07       Impact factor: 2.692

6.  Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.

Authors:  Tzvetanka Bondeva; Katrin Schindler; Claudia Schindler; Gunter Wolf
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

7.  Persistent Renin-Angiotensin System Sensitization Months After Body Weight Recovery From Severe Food Restriction in Female Fischer Rats.

Authors:  Aline M A de Souza; Hong Ji; Xie Wu; Kathryn Sandberg; Crystal A West
Journal:  J Am Heart Assoc       Date:  2020-07-17       Impact factor: 5.501

Review 8.  A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.

Authors:  Jennifer H Martin; Richard Head
Journal:  Br J Clin Pharmacol       Date:  2020-11-18       Impact factor: 3.716

9.  Elevated angiotensin II induces platelet apoptosis through promoting oxidative stress in an AT1R-dependent manner during sepsis.

Authors:  Dun-Feng Xu; Yu-Jian Liu; Yan-Fei Mao; Yan Wang; Chu-Fan Xu; Xiao-Yan Zhu; Lai Jiang
Journal:  J Cell Mol Med       Date:  2021-02-23       Impact factor: 5.310

10.  Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis.

Authors:  Hyun Woo Lee; Jae Kyung Suh; Eunjin Jang; Sang-Min Lee
Journal:  Korean J Intern Med       Date:  2020-04-09       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.